Sanofi (SNY) – What Are Investment Firms Thinking About This Stock?

Sanofi (NASDAQ:SNY) has been given a consensus recommendation of “Hold” by the twenty-one research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $49.50.

A number of analysts have recently issued reports on the stock. Morgan Stanley set a $49.00 price objective on shares of Sanofi in a research note on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. Weiss Ratings raised shares of Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. UBS Group restated a “neutral” rating on shares of Sanofi in a research note on Thursday, September 17th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Probity Advisors Inc. boosted its holdings in shares of Sanofi by 2.0% in the third quarter. Probity Advisors Inc. now owns 22,641 shares of the company’s stock valued at $933,000 after purchasing an additional 443 shares during the period. Code Waechter LLC increased its holdings in Sanofi by 8.5% during the 3rd quarter. Code Waechter LLC now owns 15,087 shares of the company’s stock worth $622,000 after purchasing an additional 1,182 shares during the period. Mondrian Investment Partners LTD raised its position in Sanofi by 2.3% during the 3rd quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after purchasing an additional 129,575 shares in the last quarter. Kendall Capital Management bought a new stake in Sanofi during the 3rd quarter valued at $202,000. Finally, Evergreen Capital Management LLC lifted its holdings in shares of Sanofi by 23.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 20,079 shares of the company’s stock worth $828,000 after buying an additional 3,800 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Trading Down 0.9%

Shares of NASDAQ:SNY opened at $41.60 on Friday. The stock’s 50-day simple moving average is $42.43 and its two-hundred day simple moving average is $43.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The stock has a market capitalization of $100.86 billion, a price-to-earnings ratio of 21.78, a PEG ratio of 1.29 and a beta of 0.33. Sanofi has a 52-week low of $39.07 and a 52-week high of $52.68.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the company posted $3.24 earnings per share. Analysts expect that Sanofi will post 5.00 EPS for the current year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.